EGFR and benign prostatic hyperplasia: This study found that CEP has the potential to selectively inhibit the EGFR/PI3K/AKT pathway of stromal cells, which is expected to match the pathological characteristics of BPH dominated by matrix proliferation (Xu G. et al., 2024).